guid soft top-line post-lyrica growth unchang
result rel in-lin forecast sale non-gaap ep
combin impact slow us ibranc sale drove flat
y/i sale growth outlook oper basi come trim
sale forecast respect driven ibranc
slightli beat forecast global basi sale key us market miss
thu lower forecast metastat indic reflect slow
us script growth competit market dynam revenu trim come
conserv new brand sale bavencio steglatro eucrisa
conserv establish product revenu offer limit near-term growth
sale ep believ compani growth outlook dramat
improv post-lyrica ep compound-annual-growth-rate model chang
result updat po mainli ep trim reiter buy
rate given undemand valuat highli defens pipelin readout offer upsid
view
takeaway call
focu result growth manag field numer
question sale growth guidanc expect flat y/i oper basi
inclus product drag mainli mid-year lyrica loe
manag declin comment con sale mid-point
note real inflect point revis forecast incorpor
conserv assumpt ibrance-u tafamidi ramp continu see sale
grow mid-sd start tanezumab updat morn
provid updat second oa studi look tanezumab versu placebo
overal result gener consist prior includ mix
safeti updat -- slightli higher rate rpoa vs singl case
osteonecrosi imbal total joint replac look ahead key de-
risk tanezumab long-term safeti trial equal import fda advisori
committe key upsid driver low back pain readout assum
bone/joint safeti issu isol oa popul commentari
manag downplay larg deal consist prior messag
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
loe loss exclus
fda us food drug
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
increas dcf termin growth rate assumpt roll
forward dcf termin year account lower base due
project ibranc loe
price object po base blend averag dcf forward price-to-earnings po
impli stock could trade ep current multipl
consensu ep multipl base regress
analysi histor us major pharma forward month price-to-earnings multipl year
forward compound-annual-growth-rate ep believ dcf analysi base reason assumpt
includ sale compound-annual-growth-rate driven key growth brand
xeljanz ibranc xtandi post-lyrica loe flat sale growth follow
downward rebas us sale pipelin overal
sale forecast out-year sale dcf assum wacc
tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
